View Future GrowthHLB Genex 過去の業績過去 基準チェック /36HLB Genexは、平均年間37.3%の収益成長を遂げていますが、 Chemicals業界の収益は、年間 減少しています。収益は、平均年間0.3% 14.7%収益成長率で 成長しています。 HLB Genexの自己資本利益率は40.6%であり、純利益率は48.3%です。主要情報37.27%収益成長率35.85%EPS成長率Chemicals 業界の成長13.95%収益成長率14.66%株主資本利益率40.61%ネット・マージン48.29%前回の決算情報31 Mar 2026最近の業績更新分析記事 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.すべての更新を表示Recent updates分析記事 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.お知らせ • Mar 17HLB Genex, Inc., Annual General Meeting, Mar 30, 2026HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea分析記事 • Feb 02These 4 Measures Indicate That HLB Genex (KOSDAQ:187420) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • May 22HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion.HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd. For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion. The expected completion of the transaction is May 26, 2025.New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m).New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m).お知らせ • Mar 14HLB Genex, Inc., Annual General Meeting, Mar 28, 2025HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Koreaお知らせ • Dec 13GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investorsOn December 12, 2024 GenoFocus, Inc. closed the transaction.お知らせ • Oct 30GenoFocus, Inc. announced that it expects to receive KRW 55 billion in fundingGenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000.分析記事 • Oct 29There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price JumpGenoFocus, Inc. ( KOSDAQ:187420 ) shares have had a really impressive month, gaining 30% after a shaky period...お知らせ • Oct 04Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion.Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024.分析記事 • Aug 05GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Aug 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m).分析記事 • Apr 13Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 24New 90-day low: ₩7,700The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.分析記事 • Feb 16Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?It hasn't been the best quarter for GenoFocus, Inc. ( KOSDAQ:187420 ) shareholders, since the share price has fallen...Is New 90 Day High Low • Jan 18New 90-day low: ₩8,800The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.分析記事 • Dec 22Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Sep 23New 90-day high: ₩16,900The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.お知らせ • Aug 30GenoFocus, Inc. announced that it has received KRW 10 billion in fundingOn August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction.お知らせ • Aug 22GenoFocus, Inc. announced that it expects to receive KRW 10 billion in fundingGenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company.収支内訳HLB Genex の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A187420 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2644,34621,4147,6435,98031 Dec 2543,37022,5917,2185,90330 Sep 2540,950-3,2676,4907,93630 Jun 2539,914-886,0638,28931 Mar 2539,009-18,5675,6439,66531 Dec 2435,430-18,8285,34310,27130 Sep 2434,8341,0452,3708,92930 Jun 2432,197-2,8563,91111,02131 Mar 2428,048-1,4443,84110,99731 Dec 2327,008-2,9504,02511,60830 Sep 2325,340-15,8795,88213,05030 Jun 2325,467-13,6684,35611,89131 Mar 2327,827-13,7064,47612,14731 Dec 2227,802-12,9684,23011,68130 Sep 2227,274-8,8374,18311,54130 Jun 2227,140-8,6413,71611,45731 Mar 2226,427-8,2223,36011,57031 Dec 2125,874-6,8172,91310,41330 Sep 2122,921-10,3122,82810,37030 Jun 2120,533-10,2982,5679,81031 Mar 2119,258-13,0352,4518,27431 Dec 2018,769-12,2172,3648,02530 Sep 2018,853-5,1422,2905,92230 Jun 2017,807-5,7292,1815,14931 Mar 2016,287-5,9072,1894,98331 Dec 1914,942-5,7592,1514,26130 Sep 1912,878-5,9521,9753,40130 Jun 1913,169-3,4271,9282,14431 Mar 1912,388-3,0201,7671,20231 Dec 1811,518-2,3231,80889930 Sep 1811,592-431,64967130 Jun 1811,1384331,64553731 Mar 1811,6851,4571,77235931 Dec 1711,5061,4111,59435230 Sep 1710,9222,0441,58929530 Jun 179,8952,2141,53236031 Mar 178,0542,1231,30233131 Dec 167,0291,6151,26526530 Sep 166,5628741,18824730 Jun 166,4611,2431,14612431 Mar 166,6541,1871,07110831 Dec 156,6401,21197813630 Sep 158,4103,19291020330 Jun 157,7962,569858208質の高い収益: A187420 非現金収入 のレベルが高いです。利益率の向上: A187420過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A187420過去 5 年間で収益を上げており、収益は年間37.3%増加しています。成長の加速: A187420は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: A187420昨年収益を上げたため、昨年の収益成長をChemicals業界 ( -3.5% ) と比較することは困難です。株主資本利益率高いROE: A187420の 自己資本利益率 ( 40.6% ) は 傑出している と考えられます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 09:29終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HLB Genex, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...
Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
分析記事 • May 26We Believe HLB Genex's (KOSDAQ:187420) Earnings Are A Poor Guide For Its ProfitabilityThe latest earnings release from HLB Genex, Inc. ( KOSDAQ:187420 ) disappointed investors. We did some analysis and...
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.
お知らせ • Mar 17HLB Genex, Inc., Annual General Meeting, Mar 30, 2026HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea
分析記事 • Feb 02These 4 Measures Indicate That HLB Genex (KOSDAQ:187420) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • May 22HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion.HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd. For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion. The expected completion of the transaction is May 26, 2025.
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m).
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m).
お知らせ • Mar 14HLB Genex, Inc., Annual General Meeting, Mar 28, 2025HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Korea
お知らせ • Dec 13GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investorsOn December 12, 2024 GenoFocus, Inc. closed the transaction.
お知らせ • Oct 30GenoFocus, Inc. announced that it expects to receive KRW 55 billion in fundingGenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000.
分析記事 • Oct 29There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price JumpGenoFocus, Inc. ( KOSDAQ:187420 ) shares have had a really impressive month, gaining 30% after a shaky period...
お知らせ • Oct 04Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion.Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024.
分析記事 • Aug 05GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Aug 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m).
分析記事 • Apr 13Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 24New 90-day low: ₩7,700The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
分析記事 • Feb 16Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?It hasn't been the best quarter for GenoFocus, Inc. ( KOSDAQ:187420 ) shareholders, since the share price has fallen...
Is New 90 Day High Low • Jan 18New 90-day low: ₩8,800The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.
分析記事 • Dec 22Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Sep 23New 90-day high: ₩16,900The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.
お知らせ • Aug 30GenoFocus, Inc. announced that it has received KRW 10 billion in fundingOn August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction.
お知らせ • Aug 22GenoFocus, Inc. announced that it expects to receive KRW 10 billion in fundingGenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company.